Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18402953 | ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONS | January 2024 | December 2025 | Allow | 23 | 1 | 0 | No | No |
| 18392013 | COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS | December 2023 | December 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18392008 | COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDER | December 2023 | December 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18543203 | ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL | December 2023 | September 2025 | Allow | 21 | 3 | 1 | No | No |
| 18532876 | METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEX | December 2023 | November 2025 | Allow | 24 | 2 | 0 | No | No |
| 18386758 | METHOD OF TREATING A GLAZED CERAMIC ARTICLE | November 2023 | April 2025 | Allow | 18 | 0 | 0 | No | No |
| 18492136 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | October 2023 | July 2025 | Allow | 21 | 1 | 1 | No | No |
| 18381436 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | October 2023 | December 2025 | Allow | 26 | 1 | 0 | No | No |
| 18286914 | NANOPARTICULATE COMPOSITIONS | October 2023 | October 2025 | Allow | 24 | 0 | 0 | Yes | No |
| 18379598 | Botanical Film-Forming Acne Compositions | October 2023 | June 2025 | Allow | 20 | 1 | 0 | No | No |
| 18457668 | SILICONE INFUSED WITH SILVER | August 2023 | August 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18233535 | MULTIPLE USE WOUND AND HEALING CREAM | August 2023 | March 2026 | Abandon | 31 | 0 | 1 | No | No |
| 18216663 | PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETES | June 2023 | February 2026 | Allow | 31 | 3 | 1 | No | No |
| 18330238 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE | June 2023 | November 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18254284 | ANTIPERSPIRANT COMPOSITIONS | May 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18251645 | ANTISEPTIC COMPOSITION | May 2023 | March 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18133349 | AQUEOUS FORMULATIONS OF TOPIRAMATE | April 2023 | February 2025 | Allow | 22 | 3 | 1 | No | No |
| 18296270 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | April 2023 | April 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18022018 | Therapeutic And Cosmetic Wound Treatment | February 2023 | March 2026 | Abandon | 37 | 1 | 1 | No | No |
| 18041419 | AN AEROSOL COMPOSITION FOR ELIMINATING PATHOGENIC MICROORGANISMS | February 2023 | November 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18107788 | PERACETIC ACID ANTIMICROBIAL COMPOSITION SYSTEM AND METHOD | February 2023 | January 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18167056 | FORMULATIONS OF PILOCARPINE AND BRIMONIDINE COMPOUNDS AND RELATED METHODS | February 2023 | August 2024 | Allow | 18 | 3 | 0 | No | No |
| 18017296 | DISINFECTING, SKIN-TOLERABLE, SUPERFATTING CARE AGENT FOR APPLICATION TO THE SKIN | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18003174 | Hydrophilic Degradable Microspheres for Local Delivering of Glycopeptide Antibiotics and Polycationic Peptide Antibiotics | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 18086679 | ANTISEPTIC COMPOSITIONS | December 2022 | December 2024 | Allow | 24 | 4 | 1 | Yes | No |
| 17980256 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | November 2022 | October 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17965253 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | October 2022 | February 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17954703 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | September 2022 | January 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17931139 | METHOD FOR THE TREATMENT OF VIRAL INFECTIONS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17905867 | MEDICINE LOADED NANO-CAPSULE ADDITIVE PMMA CEMENT | September 2022 | October 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17897666 | METHOD FOR DISINFECTION OF ITEMS AND SPACES | August 2022 | July 2023 | Allow | 11 | 1 | 0 | No | No |
| 17799871 | EXOGENOUS NITRIC OXIDE FOR IMPROVED SUSCEPTIBILITY AND LOWERED ANTIBIOTIC RESISTANCE IN RESISTANT RESPIRATORY BACTERIA | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17799543 | HUMAN CD47-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17819076 | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS | August 2022 | February 2023 | Allow | 6 | 0 | 0 | No | No |
| 17882334 | Therapeutic Gas Microfoam for Skin Recovery | August 2022 | October 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17877701 | HAND SANITIZER MICROEMULSION | July 2022 | July 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17796584 | ANTIOXIDANT OR SKIN STRESS INHIBITOR | July 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17859692 | ANTIBIOTIC COMPOSITION COMPRISING A COMPOSITE OF DIATOMACEOUS EARTH AND ZINC OXIDE, AND COMBINATION PREPARATION WITH THE SAME | July 2022 | March 2026 | Allow | 44 | 2 | 0 | No | No |
| 17859040 | ANTIPERSPIRANT COMPOSITIONS | July 2022 | June 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17842689 | IMPLANTABLE PHARMACEUTICAL COMPOSITION PREPARED FROM COMPONENTS CONSISTING OF CALCIUM SULFATE ALPHA-HEMIHYDRATE, VANCOMYCIN AND GENTAMICIN | June 2022 | July 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17784839 | DEODORIZING COMPOSITION | June 2022 | September 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17783889 | Antimicrobial Composition | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17836597 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | June 2022 | October 2024 | Allow | 28 | 3 | 0 | No | No |
| 17831705 | ANTIMICROBIAL AGENT AND ANTIMICROBIAL RESIN COMPOSITION COMPRISING THE SAME | June 2022 | June 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17738037 | pH/CO2-RESPONSIVE SMART ANTI-PATHOGEN COATINGS THAT CONTROL, REPEL, AND/OR INACTIVATE VIRUSES AND BACTERIA | May 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17736443 | METHODS FOR INHIBITING PATHOGENIC INFECTION AND INHIBITING GROWTH OF PATHOGENS | May 2022 | December 2025 | Allow | 43 | 5 | 1 | No | No |
| 17657508 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF RSV AND CORONAVIRUS INFECTION | March 2022 | January 2025 | Abandon | 33 | 4 | 1 | Yes | No |
| 17704653 | COMPOSITION FOR CONTROLLING INDIGENOUS BACTERIAL FLORA IN THE SKIN | March 2022 | March 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17691532 | SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS | March 2022 | June 2025 | Allow | 39 | 0 | 0 | No | No |
| 17688915 | ANTIMICROBIAL BIOCOMPATIBLE CO-DOPED MAGNESIUM OXIDE NANOCOMPOSITE COMPOSITIONS | March 2022 | September 2023 | Allow | 18 | 1 | 1 | No | No |
| 17637104 | ANTISEPTIC APPLICATIONS OF METAL NANOPARTICLE AGGLOMERATES | February 2022 | September 2025 | Allow | 43 | 4 | 1 | No | Yes |
| 17583738 | Praziquantel Formulations | January 2022 | April 2025 | Allow | 38 | 3 | 2 | Yes | No |
| 17570957 | POWDER FORMULATION FOR INGREDIENT DISPERSION | January 2022 | December 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17557135 | ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL | December 2021 | September 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17542838 | OCULAR INSERT COMPOSITION OF A SEMI-CRYSTALLINE OR CRYSTALLINE PHARMACEUTICALLY ACTIVE AGENT | December 2021 | August 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17535556 | Sunscreen Compositions | November 2021 | September 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17609887 | RANDOM COPOLYMER STABILIZED NANOPARTICLES ENCAPSULATING SOLUBLE HYDROPHILIC COMPOUNDS | November 2021 | May 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17521198 | Orally Administrable Composition | November 2021 | December 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17517905 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | November 2021 | August 2023 | Allow | 21 | 0 | 1 | Yes | No |
| 17506476 | STABLE ANHYDROUS DISINFECTANT CONCENTRATE FORMULATION AND METHOD OF MAKING THE SAME | October 2021 | October 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17499374 | ANTIMICROBIAL COATING FOR FOOD CONTACT SURFACES | October 2021 | February 2026 | Abandon | 52 | 1 | 1 | No | No |
| 16974374 | CHEMICAL FORMULATIONS AND THEIR USE IN NEUTRALIZING OR ELIMINATING ODORS | September 2021 | June 2025 | Abandon | 46 | 4 | 1 | No | No |
| 17463654 | USE OF AN ANTIMICROBIAL COMPOSITION | September 2021 | July 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17458674 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | August 2021 | July 2025 | Allow | 47 | 6 | 1 | Yes | No |
| 17410613 | ANTIMICROBIAL BLADDER ADDITIVES SYSTEM AND METHOD | August 2021 | October 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17387196 | LONG-WEARING COSMETIC COMPOSITION COMPRISING EXPANDED PERLITE | July 2021 | January 2026 | Abandon | 54 | 6 | 1 | No | No |
| 17381445 | ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONS | July 2021 | September 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17364386 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION | June 2021 | October 2025 | Allow | 52 | 1 | 0 | No | No |
| 17312551 | MICROBIOSTATIC SOAP THAT REDUCES THE TRANSMISSION OF MICROBES | June 2021 | June 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17311561 | OCULAR HYDROGEL COMPOSITIONS | June 2021 | February 2026 | Abandon | 56 | 4 | 1 | No | No |
| 17287105 | COMPOSITIONS FOR ADMINISTRATION TO RUMINANT ANIMALS | April 2021 | November 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17223124 | DRUG DELIVERY SYSTEM | April 2021 | March 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17216341 | METHODS OF ADMINISTERING ANIONIC CANNABINOIDS DISSOLVED IN WATER | March 2021 | July 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17279812 | ANTIMICROBIAL MIXTURES COMPRISING AT LEAST ONE HYDROXYPHENONE DERIVATIVE | March 2021 | September 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17203429 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | March 2021 | July 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17178692 | BOTANICAL FILM-FORMING ACNE COMPOSITIONS | February 2021 | July 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17267024 | ABSORBABLE BONE WAX AND PREPARATION METHOD THEREOF | February 2021 | October 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17165754 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | February 2021 | August 2024 | Abandon | 42 | 4 | 1 | Yes | Yes |
| 17163848 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | February 2021 | September 2021 | Allow | 7 | 1 | 1 | Yes | No |
| 17146662 | SYNERGISTIC METHODS OF USING BENZOXABOROLE COMPOUNDS AND PRESERVATIVE GASES AS AN ANTIMICROBIAL FOR CROPS | January 2021 | September 2024 | Allow | 44 | 2 | 1 | No | No |
| 17146128 | HYPOCHLORITE BASED HARD SURFACE DISINFECTANTS | January 2021 | May 2025 | Allow | 52 | 5 | 0 | Yes | No |
| 17120856 | PRODUCT | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 16972008 | LOW GLYCEMIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17059428 | MILD COMPOSITION FOR USE IN TOPICAL TREATMENT OF SKIN AND NAIL DISORDERS CAUSED BY VIRUS AND FUNGUS | November 2020 | April 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17084514 | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | October 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17083232 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | October 2020 | October 2022 | Allow | 23 | 0 | 0 | No | No |
| 17077897 | OXYGENATED SKIN LOTION | October 2020 | October 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17077969 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | October 2020 | January 2025 | Abandon | 51 | 8 | 0 | Yes | No |
| 17070365 | ANTIMICROBIAL COMBINATIONS SYSTEM AND METHOD | October 2020 | December 2023 | Abandon | 38 | 2 | 1 | No | No |
| 17067676 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17067259 | TOPICAL FORMULATIONS COMPRISING STRONTIUM AND METHYLSULFONYLMETHANE (MSM) AND METHODS OF TREATMENT | October 2020 | October 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 17060121 | Antibacterial and Non-Clumping Liquid Spray | October 2020 | January 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17042473 | ANTIPERSPIRANT PRODUCTS | September 2020 | February 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17033294 | TREATMENT AND PROPHYLAXIS OF RADIATION DERMATITIS | September 2020 | August 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17040825 | SOLUTIONS COMPRISING OZONIZED OIL | September 2020 | November 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16977048 | COMPOSITE PARTICLES | August 2020 | October 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17001726 | Slow Release Calcium Composition | August 2020 | July 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16991397 | Praziquantel Formulations | August 2020 | March 2022 | Abandon | 19 | 3 | 1 | No | No |
| 16988387 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | August 2020 | February 2025 | Abandon | 54 | 5 | 0 | No | No |
| 16941414 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | July 2020 | September 2020 | Allow | 2 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALAWADI, SARAH.
With a 11.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALAWADI, SARAH works in Art Unit 1619 and has examined 687 patent applications in our dataset. With an allowance rate of 36.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner ALAWADI, SARAH's allowance rate of 36.5% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALAWADI, SARAH receive 2.84 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALAWADI, SARAH is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by ALAWADI, SARAH. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.5% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.2% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 45.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 41% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 37.5% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 52.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 71.3% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.